45.30 0.00 (0.00%)
After hours: 6:29PM EDT
|Bid||41.00 x 100|
|Ask||46.25 x 200|
|Day's Range||44.85 - 46.35|
|52 Week Range||44.85 - 99.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.90|
Clovis Oncology, Inc. will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m.
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Clovis Oncology saw its shares close down over 10% on Monday after announcing that it has commenced two separate underwritten public offerings. Shares of Loxo ...
Clovis Oncology, Inc. announced today the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public of 100% of the principal amount of the notes, before underwriting discounts and commissions.
Clovis Oncology, Inc. announced today that it has commenced two separate underwritten public offerings of convertible senior notes and common stock.
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $130 million.
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
NEW YORK, NY / ACCESSWIRE / April 9, 2018 / U.S. equities experienced weekly losses last week as rising concerns over a potential trade war continued to pressure markets lower on Friday. The Dow Jones ...
The FDA sees promise in speeding the Boulder-based company's drug to a larger range of patients.
Clovis popped midday Friday after the FDA approved another use for its ovarian cancer drug Rubraca — prodding shares of rival Tesaro to topple.
Clovis Oncology, Inc. today announced that the U.S. Food and Drug Administration has approved Rubraca® tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Analysts were split Tuesday on the results of a study combining drugs from Tesaro and Merck in ovarian cancer.
Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Clovis Oncology Inc’s (NASDAQ:CLVS): Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The US$2.93B market-cap company announcedRead More...
A panel of European Medicines Agency has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity. However, the EMA's Committee for ...
Clovis Oncology, Inc. today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer.
Clovis Oncology, Inc. today announced that the European Union’s European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated , high-grade epithelial ovarian, fallopian tube, ...
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 29.